AbbVie to acquire Pharmacyclics, aiming to create leading hematological oncology franchise

5 March 2015
mergers-acquisitions-big

US drugmaker AbbVie (NYSE:ABBV) revealed late yesterday that it has reached agreement to acquire US biopharma company Pharmacyclics (Nasdaq: PCYC) and its flagship asset Imbruvica (ibrutinib), a highly effective treatment for hematologic malignancies.

The news came just as rumors of a takeover from two other companies were circulating. Already up 6.3% to $230.48 in regular trading, Pharmacyclics stock gained a further 2.9% to $237.20 in after-hours trading yesterday.

The acquisition accelerates AbbVie’s clinical and commercial presence in oncology, strengthening its already robust pipeline, and establishing its strong leadership position in hematological oncology – an attractive and rapidly growing market, now approaching $24 billion globally. The acquisition adds to AbbVie’s already comprehensive pipeline and strong growth prospects.

$21 billion transaction value

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology